title: Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
abstract: The vast majority of the human genome is transcribed into RNA molecules that do not code for proteins, which could be small ones approximately 20 nucleotide in length, known as microRNAs, or transcripts longer than 200 bp, defined as long noncoding RNAs. The prevalent deregulation of microRNAs in human cancers prompted immediate interest on the therapeutic value of microRNAs as drugs and drug targets. Many features of microRNAs such as well-defined mechanisms, and straightforward oligonucleotide design further make them attractive candidates for therapeutic development. The intensive efforts of exploring microRNA therapeutics are reflected by the large body of preclinical studies using oligonucleotide-based mimicking and blocking, culminated by the recent entry of microRNA therapeutics in clinical trial for several human diseases including cancer. Meanwhile, microRNA therapeutics faces the challenge of effective and safe delivery of nucleic acid therapeutics into the target site. Various chemical modifications of nucleic acids and delivery systems have been developed to increase targeting specificity and efficacy, and reduce the associated side effects including activation of immune response. Recently, long noncoding RNAs become attractive targets for therapeutic intervention because of their association with complex and delicate phenotypes, and their unconventional pharmaceutical activities such as capacity of increasing output of proteins. Here I discuss the general therapeutic strategies targeting noncoding RNAs, review delivery systems developed to maximize noncoding RNA therapeutic efficacy, and offer perspectives on the future development of noncoding RNA targeting agents for colorectal cancer.
authors: Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hling@mdanderson.org.
authors: Hui
authors: H
authors: Ling
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D016503:Drug Delivery Systems; D004705:Endocytosis; D005544:Forecasting; D006801:Humans; D008081:Liposomes; D035683:MicroRNAs / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000627:therapeutic use; D014677:Pharmaceutical Vehicles; D016337:RNA, Catalytic / Q000008:administration & dosage / Q000627:therapeutic use; D062085:RNA, Long Noncoding / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000037:antagonists & inhibitors; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000627:therapeutic use; D022661:RNA, Untranslated / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000627:therapeutic use*
chemical_list: D008081:Liposomes; D035683:MicroRNAs; D016376:Oligonucleotides, Antisense; D014677:Pharmaceutical Vehicles; D016337:RNA, Catalytic; D062085:RNA, Long Noncoding; D012334:RNA, Neoplasm; D034741:RNA, Small Interfering; D022661:RNA, Untranslated
keywords: Colorectal cancer; Delivery; Long noncoding RNA; MicroRNA; Mimics; Therapeutics; anti-miR